These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
156 related items for PubMed ID: 25525378
1. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease. Kukulka M, Nudurupati S, Perez MC. Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378 [Abstract] [Full Text] [Related]
2. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. Kukulka M, Wu J, Perez MC. J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130 [Abstract] [Full Text] [Related]
3. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Clin Drug Investig; 2009 Jan; 29(1):35-50. PubMed ID: 19067473 [Abstract] [Full Text] [Related]
4. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Aliment Pharmacol Ther; 2009 Nov 15; 30(10):1010-21. PubMed ID: 19735233 [Abstract] [Full Text] [Related]
5. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule. Kukulka M, Nudurupati S, Perez MC. Therap Adv Gastroenterol; 2016 Nov 15; 9(6):770-780. PubMed ID: 27803732 [Abstract] [Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole. Kukulka M, Nudurupati S, Perez MC. Therap Adv Gastroenterol; 2016 Nov 15; 9(6):759-769. PubMed ID: 27803731 [Abstract] [Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Curr Med Res Opin; 2009 Mar 15; 25(3):627-38. PubMed ID: 19232037 [Abstract] [Full Text] [Related]
10. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents. Gremse D, Gold BD, Pilmer B, Hunt B, Korczowski B, Perez MC. Dig Dis Sci; 2019 Feb 15; 64(2):493-502. PubMed ID: 30390234 [Abstract] [Full Text] [Related]
16. Dexlansoprazole for the treatment of esophagitis and GERD. Davies SL. Drugs Today (Barc); 2010 Feb 15; 46(2):75-80. PubMed ID: 20393635 [Abstract] [Full Text] [Related]